Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
3.755
-0.095 (-2.47%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Rezolute Employees
Rezolute had 59 employees as of June 30, 2024. The number of employees increased by 8 or 15.69% compared to the previous year.
Employees
59
Change (1Y)
8
Growth (1Y)
15.69%
Revenue / Employee
n/a
Profits / Employee
-$1,205,661
Market Cap
227.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
RZLT News
- 3 days ago - Rezolute, Inc. Announces Closing of Underwritten Offering - GlobeNewsWire
- 5 days ago - Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December - Benzinga
- 5 days ago - Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 days ago - Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”) - GlobeNewsWire
- 4 weeks ago - Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors - GlobeNewsWire
- 2 months ago - Rezolute: Late-Stage Study Targeting Hyperinsulinism - Seeking Alpha
- 2 months ago - Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism - GlobeNewsWire